a comparative efficacy and safety profile heat map analysis of the most promising pipeline products as well as analyses on the distribution of molecule types across the RA developmental pipeline, the molecular targets of pipeline mAbs and the developmental program types. In addition, detailed analyses of the clinical trial failure rates, the clinical trial durations by phase and clinical trial sizes by participant numbers are provided.
- Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations.
- Market forecasts across the US, the top five countries in Europe (EU5) - Germany, France, the UK, Italy, and Spain- as well as Japan. The multiple scenario forecasts take a range of factors that are likely to vary into account and provide a clear perspective on the level of the potential degree of variance in the market sizes.
- Key market drivers and barriers
- The major deals that have taken place in the monoclonal antibodies market in rheumatoid arthritis in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total value. A concomitant analysis of the licensing deal values for products by molecule types and molecular targets is also provided.
Reasons to buy
- Understand the competitive environment for monoclonal antibodies
- Develop key strategic repositioning initiatives by studying the repositioning trends and strategies of current competitors
- Understand the clinical and commercial impact of the growing diversification of the Page: 1 2 3 4 5 Related biology technology :1
. iBio Adds to iBioModulator Portfolio and Product Pipeline2
. iBio Adds New Therapeutic Antibody to Its Pipeline3
. Renal Dialysis Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 20184
. Chemotherapy Induced Nausea and Vomiting (CINV) Existing and Pipeline Drugs Market is Expected to Reach USD 2.1 Billion Globally in 2018: Transparency Market Research5
. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 20196
. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 20197
. Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 20198
. Intellect Neurosciences Adds Two New Tau Programs to its Alzheimers Disease Development Pipeline9
. Profil Institute Reports Record Growth in Number of Clinical Trials in the Pipeline10
. DuPont Leader Overviews 2012 Seed Research Pipeline with Investors11
. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics